Literature DB >> 12154039

Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis.

Shiou-Hwei Yeh1, Ching-Fung Chang, Wen-Yi Shau, Ya-Wen Chen, Hey-Chi Hsu, Po-Huang Lee, Ding-Shinn Chen, Pei-Jer Chen.   

Abstract

The CAG polymorphism in exon 1 of the androgen receptor (AR) gene has been shown associated with the development of human male hepatocellular carcinoma (HCC) with the shorter AR alleles conferring a higher risk. However, the significance of AR-CAG repeats in female hepatocarcinogenesis remains to be addressed. In this study, seventy-six pairs of female HCCs and corresponding nontumorous tissues were collected, and 180 cirrhotic nodules were microdissected from 7 cirrhotic livers. The clonality status, functional AR alleles, and CAG repeat number of each sample were determined by AR methylation analysis. In a total of 44 monoclonal HCCs, the mean of CAG repeats in the active alleles was significantly longer than that in the inactive alleles (22.0 +/- 2.8 versus 20.7 +/- 3.6; P = 0.047). When we divided HCCs into hepatitis B virus-positive [HBV(+)] and HBV(-) subgroups, the long AR allele dominance was found only in HBV(+) ones (P = 0.006 versus P = 0.923). Notably, the preference of long CAG repeat has also been found in the 100 monoclonal nodules (P = 0.013). For comparison of monoclonal nodules obtained from the same individual, a dominant long AR allele was found in 6 patients. The proportion of monoclonal cirrhotic nodules and HCCs expressing longer AR allele, 69 and 68%, are both significantly higher than 50%, the assumed value in normal liver (P < 0.001 for cirrhotic nodules and P = 0.005 for HCC). The dominance is again only prominent in HBV-infected HCCs [85% for HBV(+) HCC; P < 0.001 but 54% for HBV(-) HCC; P = 0.27]. The results indicated that in female hepatocarcinogenesis, hepatocytes expressing the longer AR allele seem to be favorably selected for autonomous growth and transformation, especially in synergy with HBV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Carly E Kelley; Ann J Brown; Anna Mae Diehl; Tracy L Setji
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

2.  Association of tri-nucleotide (CAG and GGC) repeat polymorphism of androgen receptor gene in Taiwanese women with refractory or remission rheumatoid arthritis.

Authors:  S F Yu; T T Cheng; Y H Hsu; H M Lai; Y C Chen; C K Chiu; K M Lin; C Chang; C J Chen; H Y Kang
Journal:  Clin Rheumatol       Date:  2007-04-13       Impact factor: 2.980

Review 3.  Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.

Authors:  Tatsuo Kanda; Xia Jiang; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 4.  Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?

Authors:  Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

5.  Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients.

Authors:  Xiao-Fei Zhang; Xin Yang; Hu-Liang Jia; Wen-Wei Zhu; Lu Lu; Wei Shi; Hao Zhang; Jin-Hong Chen; Yi-Feng Tao; Zheng-Xin Wang; Jun Yang; Lian-Xin Wang; Ming Lu; Yan Zheng; Jing Zhao; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

6.  Association of androgen receptor exon 1 CAG repeat length with risk of hepatocellular carcinoma: a case-control study.

Authors:  Kainan Li; Chen Zhong; Jun Wang; Baocheng Wang; Jun He; Jingwang Bi
Journal:  Tumour Biol       Date:  2014-09-14

Review 7.  The androgen receptor as an emerging target in hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Osamu Yokosuka
Journal:  J Hepatocell Carcinoma       Date:  2015-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.